PGIMER Fellowship opportunities for Life Sciences, Biotechnology, Biochemistry
3 January 2026

PGIMER Fellowship opportunities for Life Sciences, Biotechnology, Biochemistry

MSc (Immunology, Life Sciences, Biotechnology, Molecular Biology, Bioinformatics, Biochemistry, or Genomics)
3 January 2026
Apprenticeship Training Program for Pharmacy candidates at IIT
Graduate in Arts, Commerce, Science, etc. / Secretarial Practice / Modern Office Management / Pharmacy, Physiotherapy.
3 January 2026
Research Internship Program for Indian Student at USTC

The University of Science and Technology of China (USTC) research internship program provides the opportunity for graduate students or 3rd/4th year undergraduate students to participate in research projects to gain valuable experience on a variety of cutting-edge research at USTC.

3 January 2026
Amneal Pharma looking D.Pharm, B.Pharm, M.Pharm candidates in Injectable Manufacturing
M.Pharm / B.Pharm / M.Sc for Injectable Manufacturing at Amneal Pharma. Experience in bulk manufacturing/aseptic filling, control/aseptic area operation, vessel operation including CIP/SIP process handling, machine operation.
3 January 2026
Sun Pharma Require QC Senior Officer - BPharm, MSc Apply
To perform the calibration of QC instruments as per calibration schedule. Overall upkeep of respective working bench as well as of the section as per GLP.
3 January 2026
Walk In Drive for BPharm, MSc at Mankind Pharma - experience candidates can apply
The candidate must be capable of analyzing raw materials, finished products, and stability samples. Knowledge of AMV and QAMS will be given preference.
3 January 2026
Aurigene looking for DMPK Scientist - M.Pharm, MSc Apply
Experience in the development and application of pharmacometric models to support drug development and regulatory submissions.
3 January 2026
Abbott Hiring TPMQA India Head
Responsible and accountable for the oversight of quality operations and GMP compliance across the TPMs under responsibility of EPD Biosimilars Operations in India.
3 January 2026
Axsome Therapeutics secures FDA priority review for Alzheimer’s agitation treatment AXS-05

Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for AXS-05 seeking approval for the treatment of agitation associated with Alzheimer’s disease, and has granted Priority Review designation to the filing. The regulatory body has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026, underlining the importance of this potential new therapy in an area of high unmet need.

3 January 2026
Caplin Point strengthens U.S. footprint with strategic acquisition of 10 approved ANDAs
Caplin Point Laboratories Limited has announced a major strategic move to expand its presence in the regulated U.S. pharmaceutical market by acquiring ten approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic pharmaceuticals manufacturer.